Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997; 112 :251S–258S. doi: 10.1378/chest.112.4_Supplement.251S. [ Cross Ref ]Elias AD (1997) Small cell lung cancer: state-of-the-art therapy in 1996. Chest 112: 251S-258S....
1) small cell lung cancer/drug therapy 小细胞肺癌/药物治疗 2) non-small cell lung cancer/drug therapy 非小细胞肺癌/药物疗法 3) Non small cell lung carcinoma/drug therapy 非小细胞肺癌/药物疗法 4) non-small cell lung/drug therapy 非小细胞肺/药物治疗 ...
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
Small-cell lung cancer rapidly develops resistance to standard-of-care therapy. Two papers now establish xenograft models derived from patient-derived circulating tumor cells and show that initially homogeneous, chemoresponsive tumors rapidly recur as heterogeneous drug-refractory disease....
Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451 J Clin Oncol (2021), 10.1200/JCO.20.02212 Google Scholar 18 S.M. Gadgeel, N.A. Pennell, M.J. Fidler, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage...
The therapy, ZEPZELCA (lurbinectedin) has been approved by the Therapeutic Goods Administration (TGA) “for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed on or after prior platinum-containing therapy”.1 ...
Oncolytic virotherapy is an emerging biotherapeutic platform based on genetic engineering of viruses capable of selectively infecting and replicating withi... SH Thorne,DH Kirn - 《Expert Opin Biol Ther》 被引量: 68发表: 2004年 Treatment of non-small-cell lung cancer: a perspective on the rece...
Keywords: Small cell lung cancer, Immune checkpoint inhibitors, Immunotherapy, Tumor microenvironment, Combination therapy, Enhancer of zeste homolog 2 Introduction and rationale Small-cell lung cancer (SCLC) globally accounts for 13– 15% of all lung malignancies. It is a highly aggressive ...
Therapy for small cell and non-small cell lung cancer Author information: (1)University of Maryland Cancer Center, Baltimore. CP Belani,J Aisner - 《Current Opinion in Oncology》 被引量: 7发表: 1990年 Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: ...
therapies and new targeted drugs were used in research of maintenance therapy of small cell lung cancer, but the function and status of maintenance therapy in small cell lung cancer are still debated. In this paper, the research progress on the maintenance therapy of small cell lung cancer is ...